Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 2/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21823661 | 0.89 | ALPL (0.41) | ALPLAAK1DGAT1GSK3AGSK3B | |
| SCHEMBL3515303 | 0.86 | AAK1 (0.44) | ALPLAAK1DGAT1GSK3AGSK3B | |
| SCHEMBL407919 | 0.86 | ALPL (0.46) | ALPLAAK1DGAT1GSK3AGSK3B | |
| SCHEMBL29555798 | 0.86 | ALPL (0.46) | ALPLAAK1DGAT1GSK3AGSK3B | |
| SCHEMBL2067086 | 0.85 | DGAT1 (0.39) | ALPLAAK1DGAT1GSK3AGSK3B | |
| SCHEMBL19461474 | 0.84 | DGAT1 (0.43) | ALPLAAK1DGAT1SNCACSF1R | |
| SCHEMBL3515180 | 0.80 | AAK1 (0.43) | ALPLAAK1DGAT1GSK3AGSK3B | |
| SCHEMBL251502 | 0.79 | ALPL (0.45) | ALPLAAK1DGAT1GSK3AGSK3B | |
| SCHEMBL183050 | 0.78 | CSF1R (0.41) | DGAT1LPLLIPGCSF1R | |
| SCHEMBL613434 | 0.78 | AAK1 (0.46) | ALPLAAK1DGAT1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-21 | — | — | US | disclosed |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294236-B2 | Compounds as rearranged during transfection (RET) inhibitors | RET, FER, THRB | ALPL 3690/4885AAK1 992/4885DGAT1 3590/4885 |
| US-20180099976-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | ALPL 3516/4885AAK1 845/4885DGAT1 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.